Neimeth Pharmaceutical Reports N1.48bn Profit for 2025

Neimeth Pharmaceutical PLC announced a profit of N1.48 billion for the financial year ending December 31, 2025, a notable recovery from a loss of N854.5 million in 2024. The company's revenue increased by 64% to N7.37 billion, up from N4.49 billion the previous year.

J. Valentin Okelu, the Managing Director and Chief Executive Officer, highlighted the importance of patient capital for sustainable growth during the company's 2026 annual media briefing.

The turnaround was attributed to strong volume growth across key product lines and disciplined cost management strategies. Neimeth also reported a foreign exchange gain of N48 million in 2025, compared to a loss exceeding N2 billion in 2024.

The company is currently upgrading its Oregun manufacturing facility and constructing a new plant in Amawbia, Anambra State, designed to meet World Health Organization standards. Neimeth's share price rose from N5.80 at the start of the year to N9.80 by January 30, 2026, reflecting a 69% increase.